Back

Learner’s Digest International (TM)

  • Antifibrotic Agents
  • Idiopathic Pulmonary Fibrosis
  • Lung Diseases, Interstitial

Highlights from Interstitial Lung Disease: The Changing Landscape

The goal of this program is to improve management of interstitial lung disease (ILD). After hearing and assimilating this program, the clinician will be better able to: 1. Implement updated guidelines regarding the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF). 2. Appraise various treatment modalities for patients with IPF. 3. Modify treatment of ILD among patients who experience disease progression. 4. Evaluate the clinical benefits of antifibrotic agents in the treatment of ILD. 5. Recognize adverse effects associated with immunosuppres sive therapies commonly used to treat ILD.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 2 credits

MOC types

ABIM — Medical KnowledgeUp to 2 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Membership pricing — $1,095

This provider prices CME through membership. Individual courses may also be sold separately.

See plans on audio-digest.org

Listed by the provider · audio-digest.org

  • Enduring / On-demand
  • Credit · Up to 2 credits
  • MOC · Up to 2 points
  • Membership pricing
  • Released
    Sep 1, 2026
  • Last day to claim credit
    May 8, 2027 7 months left